Postoperative shoulder pain after hepatic tumor surgery
Conditions
Interventions
Control group:Intravenous administration of 10 µg sufentanil, PCIA(100mg flurbiprofen +100ug sufentanil combined with normal saline to 200ml)
Oxycodone group:Intravenous administration of 10 mg oxycodone, PCIA(100mg flurbiprofen +50ug sufentanil +50mg oxycodone combined with normal saline to 200ml)
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18–70 years; 2.ASA I–III; 3.Undergoing hepatic tumor surgery; 4.BMI <35.
Exclusion criteria
Exclusion criteria: 1)Inability to provide informed consent or communicate; 2)History of opioid abuse; 3)Coagulopathy; 4)Contraindications to epidural anesthesia; 5)Pre-existing shoulder pain prior to surgery; 6)Child-Pugh class C liver function; 7)History of shoulder arthritis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Shoulder pain scores during the first 2 postoperative days;The incidence of shoulder pain during the first 2 postoperative days; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incisional pain on the first postoperative day.;Shoulder pain score on the first postoperative day.;Incisional pain on the second postoperative day.;Shoulder pain score on the second postoperative day.;Quality of Recovery (QoR) score on postoperative day 2;The duration of surgery;The patient's pain score in the PACU;Patient's medication use in the PACU;Record the number of successful attempts at patient-controlled analgesia (PCA) activations postoperatively.;Record the number of failed attempts at patient-controlled analgesia (PCA) activations postoperatively.;Dizziness related to oxycodone;Nausea related to oxycodone;Vomiting related to oxycodone; | — |
Countries
China
Contacts
Public ContactZhang Jun
Fudan University Shanghai Cancer Center
Outcome results
None listed